The Pittsburgh Cancer Institute (PCI) is a multidisciplinary cancer research center, with programs in prevention and control, early diagnosis and treatment, education and clinical care. The PCI was formed by a consortium of the University of Pittsburgh, Carnegie Mellon University and the six hospitals affiliated with the Medical and Health Care Division of the University of Pittsburgh. The PCI maintains programs in the areas of: clinical investigations, cancer metastases, genetic aspects of carcinogenesis, immunology, viral and cellular oncogenesis, environmental and occupational aspects of carcinogenesis and experimental therapeutics. In addition, programs have been developed in epidemiology and preventive oncology, and biobehavioral oncology. The PCI maintains fifteen shared facilities to assist cancer researchers including: biostatistics office, clinical research support service, immunologic monitoring and diagnostic laboratory, serum and tissue bank, hybridoma facility, transgeneic mouse facility, flow cytometry, protein sequencing, DNA sequencing and DNA synthesis, animal facility, glassware facility, peptide synthesis, molecular genetics marker facility and library resource shared facility. This application requests continued CORE SUPPORT for the Pittsburgh Cancer Institute's programs for years 04-08.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA047904-05
Application #
3101856
Study Section
Cancer Center Support Review Committee (CCS)
Project Start
1988-08-01
Project End
1995-07-31
Budget Start
1992-09-03
Budget End
1993-07-31
Support Year
5
Fiscal Year
1992
Total Cost
Indirect Cost
Name
University of Pittsburgh
Department
Type
Schools of Medicine
DUNS #
053785812
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Sun, Weijing; Patel, Anuj; Normolle, Daniel et al. (2018) A phase 2 trial of regorafenib as a single agent in patients with chemotherapy-refractory, advanced, and metastatic biliary tract adenocarcinoma. Cancer :
Krivinko, Josh M; Erickson, Susan L; Ding, Ying et al. (2018) Synaptic Proteome Compensation and Resilience to Psychosis in Alzheimer's Disease. Am J Psychiatry 175:999-1009
Chartoumpekis, Dionysios V; Yagishita, Yoko; Fazzari, Marco et al. (2018) Nrf2 prevents Notch-induced insulin resistance and tumorigenesis in mice. JCI Insight 3:
Christner, Susan; Guo, Jianxia; Parise, Robert A et al. (2018) Liquid chromatography-tandem mass spectrometric assay for the quantitation of the novel radiation protective agent and radiation mitigator JP4-039 in murine plasma. J Pharm Biomed Anal 150:169-175
Laymon, Charles M; Minhas, Davneet S; Becker, Carl R et al. (2018) Image-Based 2D Re-Projection for Attenuation Substitution in PET Neuroimaging. Mol Imaging Biol 20:826-834
Benoist, Guillemette E; van der Meulen, Eric; van Oort, Inge M et al. (2018) Development and Validation of a Bioanalytical Method to Quantitate Enzalutamide and its Active Metabolite N-Desmethylenzalutamide in Human Plasma: Application to Clinical Management of Patients With Metastatic Castration-Resistant Prostate Cancer. Ther Drug Monit 40:222-229
Singh, Krishna B; Hahm, Eun-Ryeong; Rigatti, Lora H et al. (2018) Inhibition of Glycolysis in Prostate Cancer Chemoprevention by Phenethyl Isothiocyanate. Cancer Prev Res (Phila) 11:337-346
Li, Chunlei; Song, Baobao; Santos, Patricia M et al. (2018) Hepatocellular cancer-derived alpha fetoprotein uptake reduces CD1 molecules on monocyte-derived dendritic cells. Cell Immunol :
Thakur, Prakash C; Miller-Ocuin, Jennifer L; Nguyen, Khanh et al. (2018) Inhibition of endoplasmic-reticulum-stress-mediated autophagy enhances the effectiveness of chemotherapeutics on pancreatic cancer. J Transl Med 16:190
Posluszny, Donna M; Bovbjerg, Dana H; Agha, Mounzer E et al. (2018) Patient and family caregiver dyadic adherence to the allogeneic hematopoietic cell transplantation medical regimen. Psychooncology 27:354-358

Showing the most recent 10 out of 1187 publications